A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease "ARRIVE"
Completed
Phase 3 ResultsSummary of Purpose
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 4 January 2018.
5 Jul 2007 | 12 Jul 2007 | 15 Nov 2016 | 15 Nov 2016 | 1 Jan 2018 | 15 Nov 2017 |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
- Purpose: Prevention
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
-
Bayer Clinical Trials Contact Tony Johns tony.johns.b@bayer.com Phone: 973-254-4675 2nd email contact: james.angello.b@bayer.com
tony.johns.b@bayer.com
View Trial Locations
Recruitment
- Enrollment: 12,546
- Gender: All
- Minimum Age: 55 Years
- Accepts Healthy Volunteers: No
- 748 locations, 8 countries
Principal Investigator
- Bayer Study Director
Bayer